InO is also a useful agent as a re-induction regimen for patients with CD19 antigen-negative relapse B-ALL who do not otherwise qualify for CD19 directed CAR T cells or blinatumomab. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.